Overview

Nimotuzumab in Combined With Concurrent Radiochemotherapy in the Treatment of Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Children

Status:
Recruiting

Trial end date:
2022-12-08

Target enrollment:

Participant gender:

Summary

This is a prospective, open-label, single arm, multicenter clinical study. The purpose of the study is to evaluate the clinical efficacy and safety of combination Nimotuzumab with concurrent radiochemotherapy in children with newly diagnosed diffuse intrinsic pontine glioma(DIPG).

Phase:

Phase 3

Details

Lead Sponsor:

Biotech Pharmaceutical Co., Ltd.

Treatments:

Nimotuzumab